Get the Stockscreener App
28.29
3.18%
-0.93
After Hours:
28.29
Ideaya Biosciences Inc stock is traded at $28.29, with a volume of 710.91K.
It is down -3.18% in the last 24 hours and down -1.77% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$29.22
Open:
$29.22
24h Volume:
710.91K
Relative Volume:
0.63
Market Cap:
$2.49B
Revenue:
$218.71M
Net Income/Loss:
$-113.70M
P/E Ratio:
-21.70
EPS:
-1.3034
Net Cash Flow:
$-73.47M
1W Performance:
-4.00%
1M Performance:
-1.77%
6M Performance:
-21.13%
1Y Performance:
+34.08%
1-Day Range:
$28.19
$29.59
1-Week Range:
$27.66
$29.78
52-Week Range:
$20.50
$39.28
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
28.29 | 2.57B | 218.71M | -113.70M | -73.47M | -1.3034 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Initiated | Truist | Buy |
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Sep-04-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-22-25 | Initiated | TD Cowen | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-26-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Mar-08-24 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
What IDEAYA Biosciences (IDYA)'s Darovasertib Phase 2/3 Win and Roche Deal Mean For Shareholders - Yahoo Finance
IDEAYA (IDYA) Chief Development Officer reports 297,200-share stock option holding - Stock Titan
Understanding the Setup: (IDYA) and Scalable Risk - Stock Traders Daily
IDEAYA partners with Roche on pancreatic cancer drug trial - Investing.com UK
IDEAYA partners with Roche on pancreatic cancer drug trial By Investing.com - Investing.com South Africa
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
With billions of dollars at stake, trio of Bay Area biotechs nail down deals - The Business Journals
IDEAYA Biosciences, Inc. (IDYA) Latest Stock News & Headlines - Yahoo Finance
IDEAYA to work with Roche on combo pancreatic cancer treatment - Seeking Alpha
Cantor Fitzgerald reiterates Ideaya Biosciences stock rating By Investing.com - Investing.com Canada
IDEAYA, Roche launch PRMT5 and pan-RAS collaboration - TipRanks
IDEAYA Biosciences, Inc. 8-K Filing Details for June 3, 2026: Company Information, Nasdaq Listing, and SEC Compliance - Minichart
IDEAYA Biosciences Announces Clinical Collaboration With Roche In Mtap-Deleted Ras-Mutant Pancreatic Cancer - TradingView
IDEAYA Biosciences (IDYA) teams with Roche on IDE892 and pan‑RAS combo in MTAP‑deleted pancreatic cancer - Stock Titan
Roche, IDEAYA test new drug combo for pancreatic cancers lacking targeted drugs - Stock Titan
Guggenheim Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Wedbush Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58 - Moomoo
Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating - Moomoo
Citizens reiterates Ideaya Biosciences stock rating on trial data - Investing.com
Citizens reiterates Ideaya Biosciences stock rating on trial data By Investing.com - Investing.com Canada
News Flash: Analysts Just Made A Substantial Upgrade To Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Forecasts - Sahm
IDYA Technical Analysis & Stock Price Forecast - Intellectia AI
Ideaya’s darovasertib combo shows improved survival in melanoma trial - Investing.com UK
IDYA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
IDEAYA Highlights Positive Phase 2/3 Darovasertib Trial Results - TipRanks
Darovasertib combo boosts uveal melanoma outcomes in IDEAYA (IDYA) Phase 2/3 trial - Stock Titan
Ideaya’s darovasertib combo shows improved survival in melanoma trial By Investing.com - Investing.com South Africa
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO – Compan - Financial Times
IDEAYA Holds Steady Heading Into ASCO—Traders Watch for Next Mover on IDYA - Bez Kabli
J.P. Morgan Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $66 - Moomoo
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - TradingView
Biotech IDEAYA grants new hires 221,000 options over 4 years - Stock Titan
IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference - BioSpace
IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing - Barchart.com
A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $50 to $78 - Moomoo
Which Is a Better Investment, IDEAYA Biosciences, Inc. or Zymeworks Inc. Stock? - AAII
IDEAYA posts melanoma trial gains, prepares NDA submission - MSN
IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data - MarketBeat
Janus Henderson holds 7.27M IDEAYA shares (NASDAQ: IDYA) - Stock Titan
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology - GlobeNewswire
Ideaya Biosciences stock (US45166A1025): Minor price dip amid biotech hiring push - AD HOC NEWS
Precision Trading with Ideaya Biosciences Inc. (IDYA) Risk Zones - Stock Traders Daily
Ideaya Biosciences stock (US45166A1025): Positioned in iShares Genomics ETF holdings - AD HOC NEWS
Time To Worry? Analysts Are Downgrading Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Outlook - Moomoo
Vanguard Group Inc. Buys 97,116 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62 - Moomoo
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st
Assessing IDEAYA Biosciences (IDYA) Valuation After Positive Darovasertib Phase 2/3 Results And FDA Real-Time Review - Yahoo Finance
Some Analysts Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Estimates - simplywall.st
IDEAYA Biosciences, Inc. (IDYA) reports Q1 loss, misses revenue estimates - MSN
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $53 - Moomoo
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):